Akinsanya Karen 4

What Happened
Karen Akinsanya, a director of Nautilus Biotechnology, was granted a derivative award on 2026-06-18 covering 45,000 shares. The grant is reported as acquired at $0.00 (no cash paid at grant) and is recorded as a derivative (an option) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed within the standard reporting window).
• Transaction code: A (Grant/Award); Instrument: derivative option covering 45,000 shares; reported acquisition price: $0.00.
• Vesting: Per footnote, subject to continued service as a “Service Provider,” one‑twelfth of the option vests monthly after the grant date (i.e., monthly vesting over 12 months).
• Shares owned after transaction: not specified in the provided filing.
• No indication this was a cash purchase or an immediate sale; this is a compensation award.

Context
This is an option award that will convert to vested rights over time if the insider remains a service provider; it does not represent immediately tradable shares until vesting (and possible exercise/settlement) occurs. Awards to directors are commonly part of compensation packages and do not, by themselves, signal buying or selling intent.